Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Akebia Therapeutics, Inc. (AKBA)
|
Add to portfolio |
|
|
|
| Price: |
$2.45
| | Metrics |
| OS: |
185.9
|
M
| |
|
|
| Market cap: |
$456
|
M
| |
|
|
|
Net cash:
|
|
| |
|
|
|
EV:
|
$456
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 292.6 | 213.6 | 295.3 | 335.0 | 207.7 | 181.2 | 1.5 | 0.0 |
| Revenue growth | 37.0% | -27.7% | -11.8% | 61.3% | 14.6% | 11706.3% | | |
| Cost of goods sold | 84.8 | 153.4 | 295.9 | 145.3 | 7.8 | 0.0 | 0.0 | 0.0 |
| Gross profit | 207.8 | 60.2 | -0.6 | 189.7 | 200.0 | 181.2 | 1.5 | 0.0 |
| Gross margin | 71.0% | 28.2% | -0.2% | 56.6% | 96.3% | 100.0% | 100.0% | |
| Selling, general and administrative | 138.7 | 174.2 | 153.9 | 149.5 | 87.1 | 27.0 | 22.2 | |
| Research and development | 129.1 | 147.9 | 218.5 | 323.0 | 291.0 | 230.9 | 115.8 | 43.0 |
| General and administrative | | | | | | | | 18.5 |
| EBITA | -27.1 | -229.3 | -229.4 | -249.9 | -176.6 | -76.7 | -136.5 | -61.5 |
| EBITA margin | -9.3% | -107.3% | -77.7% | -74.6% | -85.0% | -42.3% | -8889.9% | |
| Amortization of intangibles | 36.0 | 36.0 | 31.5 | 36.4 | 1.5 | | | |
| EBIT | -63.2 | -265.3 | -260.9 | -286.3 | -178.2 | -76.7 | -136.5 | -61.5 |
| EBIT margin | -21.6% | -124.2% | -88.4% | -85.5% | -85.8% | -42.3% | -8889.9% | |
| Pre-tax income | -92.6 | -282.8 | -383.5 | -286.3 | -171.9 | -73.7 | -135.7 | -60.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | -6.6 | -28.3 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 2.3% | 16.5% | 0.0% | 0.0% | 0.0% |
| Net income | -92.6 | -282.8 | -383.5 | -279.7 | -143.6 | -73.7 | -135.7 | -60.7 |
| Net margin | -31.6% | -132.4% | -129.9% | -83.5% | -69.1% | -40.7% | -8843.5% | |
| |
| Diluted EPS | ($0.51) | ($1.70) | ($2.77) | ($2.36) | ($2.47) | ($1.69) | ($3.60) | ($2.29) |
| Shares outstanding (diluted) | 182.8 | 165.9 | 138.5 | 118.4 | 58.0 | 43.5 | 37.7 | 26.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|